Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FG2216 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| FG2216 | DRUG | - |
Inclusion Criteria: * Stage 3 or 4 chronic kidney disease * appropriate hemoglobin levels Exclusion Criteria: * Neovascular age related macular degeneration requiring treatment * Macular edema or proliferative retinopathy in diabetic subjects, requiring treatment * Any history of malignancy * The...
FG2216 is an investigational small molecule being developed for the treatment of renal anemia, a condition of low red blood cell counts associated with chronic kidney disease. It is currently in Phase 2 clinical development and has not been approved by the FDA.
FG2216 is a small molecule that targets hypoxia-inducible factor (HIF) pathways, which play a role in the body's response to low oxygen levels and stimulate erythropoietin production. This mechanism is intended to address anemia in patients with renal disease.
FG2216 is being developed by Kyntra Bio, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol KYNB.
FG2216 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied for safety and efficacy in clinical trials.
FG2216 has one completed Phase 2 clinical trial, identified as NCT00456053. This randomized study evaluated the safety and efficacy of FG-2216 in 145 subjects with renal anemia who were not requiring dialysis and not receiving recombinant human erythropoietin. The trial was conducted in the United States.
Yes, FG2216 and FG-2216 refer to the same investigational drug. The compound is also known by the name FG-2216, and both names are used interchangeably in clinical research and development contexts.